close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

West Pharmaceutical Services, Inc. Common Stock (NY:WST)

280.84 +6.85 (+2.50%)
Official Closing Price Updated: 7:00 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about West Pharmaceutical Services, Inc. Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
News headline image
(WST) - Analyzing West Pharmaceutical Servs's Short Interest ↗
 
Via Benzinga
News headline image
Why NYSE:WST is a Top Pick for Dividend Investors. ↗
Is WEST PHARMACEUTICAL SERVICES (NYSE:WST) suited for dividend investing? 
Via Chartmill
News headline image
10 Best Dividend Stocks Using The Dividend Growth Signal ↗
Dividend growth is a powerful signal of a company’s financial health, management’s confidence, and commitment to long-term value creation. 
Via Talk Markets
Topics Stocks / Equities
News headline image
WEST PHARMACEUTICAL SERVICES (NYSE:WST) Exhibits Quality Stock Traits. Here's Why. ↗
WEST PHARMACEUTICAL SERVICES (NYSE:WST) Exhibits Quality Stock Traits. Here's Why. 
Via Chartmill
News headline image
Looking Into West Pharmaceutical Servs's Recent Short Interest ↗
 
Via Benzinga
News headline image
Exploring NYSE:WST's dividend characteristics. ↗
Analyzing WEST PHARMACEUTICAL SERVICES (NYSE:WST)'s Dividend Potential. 
Via Chartmill
News headline image
Why NYSE:WST qualifies as a good dividend investing stock. ↗
Uncovering Dividend Opportunities with WEST PHARMACEUTICAL SERVICES (NYSE:WST). 
Via Chartmill
News headline image
Looking Into West Pharmaceutical Servs's Recent Short Interest ↗
 
Via Benzinga
News headline image
Peering Into West Pharmaceutical Servs's Recent Short Interest ↗
 
Via Benzinga
News headline image
Balancing Dividends and Fundamentals: The Case of NYSE:WST. ↗
Analyzing WEST PHARMACEUTICAL SERVICES (NYSE:WST)'s Dividend Potential. 
Via Chartmill
News headline image
3 Dividend Aristocrats With Long-Term Growth ↗
These 3 Dividend Aristocrats have raised their dividends for over 25 years and have long-term growth potential. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Cameco, Applied Digital, West Pharmaceutical And More On CNBC's 'Final Trades' ↗
On CNBC's "Halftime Report Final Trades," Tim Seymour of Seymour Asset Management picked Cameco Corporation. 
Via Benzinga
News headline image
West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend ↗
West Pharmaceutical Services reported Q3 adjusted EPS of $1.85, beating estimates, with $746.9 million in sales. Updated 2024 guidance reflects higher EPS and sales. 
Via Benzinga
News headline image
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Earnings Outlook For West Pharmaceutical Servs ↗
 
Via Benzinga
News headline image
(WST) - Analyzing West Pharmaceutical Servs's Short Interest ↗
 
Via Benzinga
News headline image
Exploring NYSE:WST's dividend characteristics. ↗
Exploring WEST PHARMACEUTICAL SERVICES (NYSE:WST)'s dividend characteristics. 
Via Chartmill
News headline image
Is NYSE:WST a Good Fit for Dividend Investing? ↗
Why WEST PHARMACEUTICAL SERVICES (NYSE:WST) qualifies as a good dividend investing stock. 
Via Chartmill
News headline image
Build-A-Bear Workshop Posts Upbeat Earnings, Joins Affirm, Nutanix, Cooper Companies, Veeva Systems And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
S&P 500, Nasdaq 100 Mark Seventh Straight Positive Session, Strongest Week Since October 2023: Friday's Top Movers ↗
S&P 500 and Nasdaq 100 indices gain for seventh straight day, marking best weekly performance since October 2023 on positive economic data. SPY and QQQ close with modest daily gains while DIA has best... 
Via Benzinga
Topics Stocks
News headline image
Balancing Dividends and Fundamentals: The Case of NYSE:WST. ↗
Why the dividend investor may take a look at WEST PHARMACEUTICAL SERVICES (NYSE:WST). 
Via Chartmill
News headline image
Ford, Stellantis And Dell Are Among Top 12 Large Cap Losers Last Week (July 21-July 27): Are The Others In Your Portfolio? ↗
Top 10 worst performers last week: EW (-28.05%), F (-19.12%), STM (-17.60%), TER (-16.25%), MBLY (-14.61%), STLA (-13.07%), VRT (-12.04%), SMCI (-11.68%), WST (-11.37%), DELL (-11.26%), UPS (-10.96%),... 
Via Benzinga
News headline image
Why NYSE:WST is a Top Pick for Dividend Investors. ↗
Exploring WEST PHARMACEUTICAL SERVICES (NYSE:WST)'s dividend characteristics. 
Via Chartmill
News headline image
How Is The Market Feeling About West Pharmaceutical Servs? ↗
 
Via Benzinga
News headline image
Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
WST Stock Earnings: West Pharmaceutical Servs Misses EPS, Misses Revenue for Q2 2024 ↗
WST stock results show that West Pharmaceutical Servs missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Uncovering Dividend Opportunities with NYSE:WST. ↗
Why WEST PHARMACEUTICAL SERVICES (NYSE:WST) qualifies as a good dividend investing stock. 
Via Chartmill
News headline image
Peering Into West Pharmaceutical Servs's Recent Short Interest ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About West Pharmaceutical Servs? ↗
 
Via Benzinga
News headline image
WST Stock Earnings: West Pharmaceutical Servs Beats EPS, Beats Revenue for Q1 2024 ↗
WST stock results show that West Pharmaceutical Servs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today